Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy.
biomarker
gastric cancer
hyperthermic intraperitoneal chemotherapy
survival
tumor mutational burden
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
10
2021
accepted:
04
02
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC. Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study. The tumor mutational burden (TMB) was significantly higher in the group of patients with a better response to HIPEC treatment than that of the others. Kaplan-Meier survival curve showed that patients with high TMB had a significantly longer survival time than that in patients with low TMB. This discovery was validated in the replication cohort. Genes bearing mutations recurrently and selectively in patients with better response to HIPEC were found in the two cohorts. We found that higher TMB is significantly associated with better response to HIPEC. Our results provide useful hints for prognostic stratification of HIPEC treatment.
Sections du résumé
Background
UNASSIGNED
Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.
Methods
UNASSIGNED
Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.
Results
UNASSIGNED
The tumor mutational burden (TMB) was significantly higher in the group of patients with a better response to HIPEC treatment than that of the others. Kaplan-Meier survival curve showed that patients with high TMB had a significantly longer survival time than that in patients with low TMB. This discovery was validated in the replication cohort. Genes bearing mutations recurrently and selectively in patients with better response to HIPEC were found in the two cohorts.
Conclusion
UNASSIGNED
We found that higher TMB is significantly associated with better response to HIPEC. Our results provide useful hints for prognostic stratification of HIPEC treatment.
Identifiants
pubmed: 35350562
doi: 10.3389/fonc.2022.796263
pmc: PMC8958003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
796263Informations de copyright
Copyright © 2022 Zeng, Huang, Tian, Huang, Liu, Wen, Liu, Shao, Luo, Tang, Liao, Lei, Cui, Xia, Guan, Li and Cui.
Déclaration de conflit d'intérêts
Authors KL and YS are employed by Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Oncol. 2021 Jul 22;2021:3374939
pubmed: 34335754
Hum Immunol. 2009 Jul;70(7):477-86
pubmed: 19332094
Cancer Biol Med. 2014 Dec;11(4):281-4
pubmed: 25610715
Oncology. 1999;57(2):106-14
pubmed: 10461056
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Dig Surg. 2006;23(1-2):93-102
pubmed: 16763374
Cancer. 1988 Jan 15;61(2):232-7
pubmed: 3121165
Surgery. 2002 May;131(5):521-8
pubmed: 12019405
Gastric Cancer. 2001;4(1):27-33
pubmed: 11706624
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):361-5
pubmed: 20688598
Int J Oncol. 2004 Mar;24(3):609-13
pubmed: 14767545
Front Oncol. 2021 Dec 03;11:795390
pubmed: 34926311
Bioinformatics. 2016 May 1;32(9):1423-6
pubmed: 27153000
J Gastrointest Oncol. 2016 Aug;7(4):523-9
pubmed: 27563441
J Surg Res. 2005 Nov;129(1):147-51
pubmed: 15975593
Eur J Surg Oncol. 2021 Nov;47(11):2757-2767
pubmed: 34001385
J Surg Oncol. 2010 May 1;101(6):457-64
pubmed: 20401915
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1925-1931
pubmed: 32354538
J Vasc Interv Radiol. 2013 Aug;24(8):1105-12
pubmed: 23582441
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
J Clin Med. 2019 Oct 15;8(10):
pubmed: 31618869
J Int Med Res. 2019 Dec;47(12):5926-5936
pubmed: 31741406
World J Surg. 1995 May-Jun;19(3):450-4; discussion 455
pubmed: 7639005
Sci Rep. 2019 Jul 22;9(1):10572
pubmed: 31332257
Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8
pubmed: 15783058
J Hepatol. 2005 Nov;43(5):817-22
pubmed: 16087270
Am J Surg. 2010 Oct;200(4):500-6
pubmed: 20887844
Ann Oncol. 2019 Sep 1;30(9):1479-1486
pubmed: 31236579
Clin Exp Metastasis. 2016 Apr;33(4):297-307
pubmed: 26873137
Ann Surg Oncol. 2011 Jun;18(6):1575-81
pubmed: 21431408
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Annu Rev Immunol. 2002;20:395-425
pubmed: 11861608
Br J Cancer. 2015 Mar 3;112(5):851-6
pubmed: 25668003
Ann Ital Chir. 2012 May-Jun;83(3):224-31
pubmed: 22595734